How does PGT-M work?

PGT-M is designed around a known genetic condition or gene change in a family. Before IVF, a genetics and fertility team reviews the family history and available test results, then prepares a targeted laboratory method for that condition. Genetic carrier screening may be useful when the family's risk is not yet clear, but it is different from PGT-M.

During IVF, embryos develop in the laboratory until they can be biopsied. A few cells are removed from the outer layer and analysed for the specific gene change. The embryo is usually kept in storage while the laboratory completes the analysis. Testing may distinguish embryos expected to be affected, unaffected, or carriers, depending on the condition and the testing plan.

Your specialist explains which findings can be reported and how they affect transfer choices. PGT-M does not examine every possible health condition, and a result cannot predict all future health or development. A prenatal diagnostic test may still be discussed after pregnancy begins.

The pathway can involve genetic counselling, IVF, embryo biopsy, laboratory analysis, freezing, and a later transfer. Testing is especially personal when a family has experienced an inherited condition, recurrent miscarriage, or a known risk in related couples.

After IVF procedures or embryo transfer, seek prompt medical advice for severe pelvic pain, heavy bleeding, faintness, breathing difficulty, or fever. These warning signs concern the procedure or pregnancy care, not a prediction made by PGT-M.

Ask whether the family gene change has been confirmed, how the laboratory will recognise it, whether carrier status will be reported, and what happens if a result is uncertain or no suitable embryo is available.